1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Santen Pharmaceutical Co., Ltd.

Santen Pharmaceutical Co., Ltd.

SNPHY
Santen Pharmaceutical Co., Ltd.US flagOther OTC
13.06
USD
+0.18
- -
4.20BMarket Cap
Santen Pharmaceutical Co., Ltd.
SNPHY
(Other OTC)

Recent

price

13.06

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
259.41
262.64
282.26
354.41
391.79
471.96
485.19
553.48
576.18
605.16
624.86
666.02
720.24
822.75
860.39
890.12
438.05
Revenue per Share
49.94
39.39
39.16
47.78
58.18
128.99
52.94
86.76
78.67
59.17
23.31
68.08
-38.58
72.59
103.98
114.06
20.65
Basic EPS, GAAP
41.6
49.31
23.57
50.42
-99.39
32.46
3.27
80.97
60.47
76.96
37.56
25.52
32.42
168.82
- -
- -
110.59
Free Cash Flow per Basic Share
15.94
19.98
20.07
19.98
20.01
23.98
26.2
25.98
26.05
26
28.01
30
32.54
32.37
- -
- -
16.47
Dividend per Share
360.97
358.17
373.6
411.91
450.84
554.97
563.13
632.99
657.15
705.96
705.37
748.29
636.96
677.91
679.98
708.46
734.19
Book Value per Share
363.82
348.88
344.33
389.16
308.3
426.13
285.11
376.62
397.53
457.74
485.25
516.86
508.46
603.65
601.45
684.81
585.84
Tangible Book Value per Share
427
436
422
413
413
414
410
406
406
399
399
400
387
367
349
328
356
Basic Weighted Avg Shares
110,812
114,416
119,066
146,260
161,831
195,291
199,096
224,942
234,026
241,555
249,605
266,257
279,037
301,965
300,004
291,624
156,159
Sales/Revenue/Turnover
27.74
23.36
20.73
20.43
21.86
41.06
16.31
17.2
19.27
13.88
4.88
13.48
-1.11
12.76
15.63
16.39
8.61
Operating Margin (%)
2,976
2,949
3,290
2,841
6,958
9,338
9,882
10,896
10,969
16,573
17,498
17,055
17,249
18,178
8,812
8,773
9,245
Depreciation Expense
21,333
17,160
16,520
19,718
24,032
53,373
21,724
35,261
31,954
23,618
9,311
27,218
-14,948
26,642
36,256
37,369
7,361
Net Income, GAAP
31.35
38.25
35.44
35.05
32.99
32.84
27.72
10.19
25.92
32.34
21.92
23.66
- -
10.61
24.49
20.83
22.98
Effective Tax Rate (%)
19.25
15
13.87
13.48
14.85
27.33
10.91
15.68
13.65
9.78
3.73
10.22
-5.36
8.82
12.09
12.81
4.71
Profit Margin (%)
113,564
112,863
102,426
114,055
94,332
121,509
103,530
121,166
134,079
150,959
127,682
133,605
123,822
143,343
137,463
140,890
134,610
Working Capital
152
115
87
59
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
156,404
164,861
167,857
187,210
211,779
260,009
255,929
287,557
292,572
302,560
309,646
336,844
293,297
305,369
285,181
296,017
288,254
Total Equity
13.79
9.96
9.34
10.59
11.46
21.59
8.7
12.54
11.23
7.45
3.05
8.35
- -
11.28
11.84
12.87
9.95
Return on Invested Capital (%)
14.5
11.06
10.53
12.2
13.6
26.15
10.52
14.53
12.93
9.87
3.79
9.72
- -
11.72
15.99
16.59
10.83
Return on Capital (%)
14.52
11.06
10.53
12.04
13.49
25.67
9.43
14.44
12.19
8.61
3.3
9.37
-5.48
10.75
14.92
15.93
2.82
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
363
- -
349
Market Capitalization
534,953
587,514
648,713

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
236,139
- -
218,478
Cash, Cash Equivalents & STI
94,961
- -
85,918
Accounts Receivable, Net
90,539
- -
71,124
Inventories
43,185
- -
53,060
Total Current Liabilities
92,796
- -
83,868
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.54%
-0.57%
3.8%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-29.47%
-40.33%
3.07%
Sales/Revenue/Turnover
4.18%
3.25%
-2.79%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
72,389
73,417
77,027
79,132
301,965
2025
- -
- -
- -
- -
300,004
2026
- -
- -
- -
- -
291,624

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
27.94
24.6
20.73
- -
72.59
2025
- -
- -
- -
- -
103.98
2026
- -
- -
- -
- -
114.06

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
15.88
0.24
16.36
- -
32.37
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Tdspharm (464280.KQ)
Otsuka Holdings Co., Ltd. (4578.T)
AstraZeneca PLC (AZNCF)
Johnson & Johnson (JNJ)
Santen Pharmaceutical Co., Ltd. (SNPHY)
Senores Pharmaceuticals Ltd. (SENORES.NS)
Business
Santen Pharmaceutical Co., Ltd. (SNPHY) is a global pharmaceutical company specializing in the research, development, manufacturing, marketing and sales of prescription ophthalmic pharmaceuticals, over-the-counter eye care products and medical devices focused on ophthalmology. Founded in 1890 and headquartered in Osaka, Japan, the company offers a portfolio exceeding 70 products addressing glaucoma, dry eye disease, ocular allergies, uveitis, myopia, ptosis, meibomian gland dysfunction and retinal disorders; key offerings include tafluprost/timolol maleate combination eye drops, ciclosporin ophthalmic emulsion for vernal keratoconjunctivitis, latanoprost emulsion, epinastine hydrochloride for allergic conjunctivitis, netarsudil mesylate/latanoprost fixed-dose combination, sepetaprost prostaglandin analogue, atropine sulfate for juvenile myopia, olodaterol hydrochloride for dry eye and sirolimus ophthalmic suspension for Fuchs endothelial corneal dystrophy. Santen operates in over 60 countries across Japan, China, Asia, Europe, the Middle East, Africa and the Americas, with prescription pharmaceuticals comprising the majority of revenue alongside over-the-counter products and surgical devices. In recent developments, Santen launched SETANEO Ophthalmic Solution 0.002% in Japan in October 2025 for glaucoma and ocular hypertension treatment, resumed shipments of DIQUAS LX Ophthalmic Solution 3% for dry eye in December 2025 following a temporary suspension and announced a collaboration with the Singapore Eye Research Institute in December 2025 to advance disease-modifying therapies for major eye diseases. The company entered a licensing agreement with Cloudbreak Pharma in September 2024 for a topical pterygium treatment in Japan and beyond, secured exclusive commercialization rights in China for Arctic Vision's ARVN001 uveitic macular edema therapy via an USD 85 million deal in late 2024 and progressed with RemeGen on RC28-E intravitreal injection, including BLA acceptance in China for diabetic macular edema in September 2025.

Company News

APIChatGPT

  • defenseworld.net

    Santen Pharmaceutical (OTCMKTS:SNPHY) & Otsuka (OTCMKTS:OTSKY) Financial Review

  • defenseworld.net

    Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Update